Humaid Al-Shamsi, The Chairman of Nexomic, CEO of Burjeel Cancer Institute (BCI) Comprehensive Cancer Center, shared on LinkedIn:
“A significant milestone for Burjeel Cancer Institute | BCI.
Burjeel Cancer Institute | BCI has achieved the highest number of abstracts accepted at ESMO – European Society for Medical Oncology 2026 from a single cancer center in the UAE, with nine abstracts accepted for presentation.
This reflects the strength of our clinical research programme and the commitment of our physicians, researchers, and multidisciplinary teams to advancing cancer care through evidence-based innovation.
Research is a key part of delivering world-class oncology services. Every abstract represents work that has the potential to improve patient care, contribute to international scientific knowledge, and reinforce the UAE’s growing presence in global oncology.
Congratulations to everyone involved in this achievement. We look forward to presenting our work at ESMO 2026 in Madrid.”
